

03-28-2002

Attorney Docket No. PC 22003AADO

FORM PTO-1595

1-31-92



HEET

U.S. DEPARTMENT OF COMMERCE

Patent and Trade

To the Assistant Commissioner of Patents &amp;

102034595

al documents or copy thereof.

## 1. Name of conveying party(ies):

Charlotte Moira Norfor Allerton, Kevin Neil Dack and  
Mark Ian Kemp

3-14-02

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

## 3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other

Execution Date: March 7, 2002

## 2. Name and address of receiving party(ies):

Name: Pfizer Inc.Street Address: 235 East 42nd Street, (150/5)City: New York State: New York Zip: 10017-5755

and

Name: \_\_\_\_\_

Internal Address: \_\_\_\_\_

Street Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Additional name(s) & address(es) attached? ☐ Yes ☒ No

## 4. Application number(s) or patent number(s):

10,099,264

If this document is being filed together with a new application, the execution date of the application is: March 7, 2002

A. Patent Application No.(s)

B. Patent No. (s)

Additional numbers attached? ☐ Yes ☒ No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Gregg C. BensonInternal Address: Pfizer Inc.Street Address: Eastern Point Road, MS 8260-1611City: Groton State: Connecticut ZIP: 06340

## 6. Total number of pages including cover sheet, attachments and document: 2

7. Total fee (37 CFR 3.41).....\$ 40.00☐ Enclosed☒ Authorized to be charged to deposit account

## 8. Deposit account number:

16-1445

(Attach duplicate copy of this page if paying by deposit account)

03/27/2002 LMUELLER 00000125 161445 10099264

01 FC:581 40.00 CH

DO NOT USE THIS SPACE

## 9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached document is the original or a true copy of the original document.*

A. Dean Olson

Name of Person Signing

Signature

3/13/2002

Date

Total number of pages including cover sheet: 2

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Box Assignment

Director - U.S. Patent and Trademark Office

Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

CONFORMS WITH FORM PTO-1595

EXPRESS MAIL NO.

ASSIGNMENT RECORDAL CVR SHEET (GROTON) TO ASST COMMIS (NEW FILING).DOT, 10/01


EL912062554 US


PATENT  
 REEL: 012714 FRAME: 0016

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged we **Charlotte Moira Norfor ALLERTON, Kevin Neil DACK and Mark Ian KEMP** of Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom, hereby sell, assign and transfer unto **PFIZER INC.**, a corporation organised and existing under the laws of the State of Delaware, and having a place of business at 235 East 42<sup>nd</sup> Street, New York, N.Y. 10017, United States of America, the entire right, title, and interest in and to our application for Letters Patent of the United States, executed the 07 day of March 2002 entitled **PHARMACEUTICALLY ACTIVE COMPOUNDS** and our entire right, title and interest in the United States in and to all our inventions, whether joint or sole, disclosed in said application for Letters Patent, and in and to all United States patents granted on the foregoing inventions, and we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.


Signed and witnessed this 07 day of March 2002  
at Sandwich, Kent, England.

  
Charlotte Moira Norfor ALLERTON

  
Kevin Neil DACK

  
Mark Ian KEMP

In the presence of:

  
A. Dunk (Witness)

# COPY

Attorney Docket No. PC 22003AADO

FORM PTO-1595  
1-31-92**RECORDATION FORM COVER SHEET  
PATENTS ONLY**U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark

To the Assistant Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):  
Charlotte Moira Norfor Allerton, Kevin Neil Dack and  
Mark Ian KempAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ OtherExecution Date: March 7, 2002

2. Name and address of receiving party(ies):

Name: Pfizer Inc.Street Address: 235 East 42nd Street, (150/5)City: New York State: New York Zip: 10017-5755

and

Name: \_\_\_\_\_

Internal Address: \_\_\_\_\_

Street Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: March 7, 2002

A. Patent Application No.(s)

B. Patent No. (s)

Additional numbers attached? ☐ Yes ☒ No5. Name and address of party to whom  
correspondence concerning document should be  
mailed:Name: Gregg C. BensonInternal Address: Pfizer Inc.Street Address: Eastern Point Road, MS 8260-1611City: Groton State: Connecticut ZIP: 063406. Total number of pages including cover sheet,  
attachments and document: 27. Total fee (37 CFR 3.41).....\$ 40.00☐ Enclosed☒ Authorized to be charged to deposit account

8. Deposit account number:

16-1445

(Attach duplicate copy of this page if paying by deposit account)

**DO NOT USE THIS SPACE**

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached document is the original or a true copy of the original document.*

A. Dean Olson

Name of Person Signing

Signature

Date

Total number of pages including cover sheet: 2

OMB No. 0651-0011 (exp. 4/94)

**Do not detach this portion**

Mail documents to be recorded with required cover sheet information to:

**Box Assignment****Director - U.S. Patent and Trademark Office****Washington, D.C. 20231**

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

CONFORMS WITH FORM PTO-1595

**EXPRESS MAIL NO.**

ASSIGNMENT RECORDAL CVR SHEET (GROTON) TO ASST COMMIS (NEW FILING).DOT, 10/01


EL912062554 US**PATENT****REEL: 012714 FRAME: 0018**

Joint Inventors  
Pfizer - US Only

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged we **Charlotte Moira Norfor ALLERTON, Kevin Neil DACK and Mark Ian KEMP** of Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom, hereby sell, assign and transfer unto **PFIZER INC.**, a corporation organised and existing under the laws of the State of Delaware, and having a place of business at 235 East 42<sup>nd</sup> Street, New York, N.Y. 10017, United States of America, the entire right, title, and interest in and to our application for Letters Patent of the United States, executed the 07 day of March 2002 entitled **PHARMACEUTICALLY ACTIVE COMPOUNDS** and our entire right, title and interest in the United States in and to all our inventions, whether joint or sole, disclosed in said application for Letters Patent, and in and to all United States patents granted on the foregoing inventions, and we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.


Signed and witnessed this 07 day of March 2002  
at Sandwich, Kent, England.

  
Charlotte Moira Norfor ALLERTON

  
Kevin Neil DACK

  
Mark Ian KEMP

In the presence of:

  
A. Dunk (Witness)